Disc Medicine Q2 net loss $55.2M; on track for bitopertin NDA in October 2025

Disc Medicine, Inc.

2025-Q2 EPS reported -$2.61

Cash of $650.0M as of June 30, 2025; expected to fund operations into 2028.
NDA submission for bitopertin in EPP under accelerated approval planned for October 2025 after positive pre-NDA meeting.
Phase 2 data from DISC-0974 in MF anemia and multiple-dose data from Phase 1b in NDD-CKD anemia expected Q4 2025.
Initiated Phase 2 study of DISC-3405 in polycythemia vera; initial data anticipated in 2026.
Appointed Nadim Ahmed (Cullinan Therapeutics CEO) to Board of Directors in July 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.